查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423675

到 2030 年陰道炎治療藥物市場預測：按疾病類型、治療、分銷管道和地區進行的全球分析

Vaginitis Therapeutics Market Forecasts to 2030 - Global Analysis By Disease Type, By Treatment, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球陰道炎治療藥物市場規模為 35.2 億美元，預計預測期內複合年成長率為 10.3%，到 2030 年將達到 70.1 億美元。

陰道炎藥物包括旨在治療陰道發炎和稱為陰道炎的感染的醫療干預措施。常見原因包括細菌、真菌和病毒感染，治療通常涉及抗生素、抗真菌藥物和抗病毒藥物。此外，管理荷爾蒙失衡和刺激物等潛在因素也很重要。個人化護理包括局部和內服藥物藥物、生活方式的改變以及解決影響因素以緩解症狀和恢復陰道健康。

根據 CDC 的數據，大約 30% 的美國女性經常患有陰道炎。

提高對女性健康和陰道炎的認知

提高對女性健康和陰道感染疾病的認知已成為陰道炎治療的重要動力。它提倡積極主動的醫療保健方法，鼓勵婦女及早發現症狀、及時就醫並採取預防措施。這種意識將促進教育舉措，鼓勵公開討論，並減少圍繞陰道健康問題的恥辱。這會改善就醫行為、早期診斷和及時干預，從而推動對有效治療方法的需求。

有限的醫療服務

醫療機會有限是陰道炎治療藥物的重要阻礙因素。存在障礙，包括醫療保健基礎設施不足，特別是在農村和服務不足地區，以及醫療設施和專家的數量減少。此外，經濟限制和獲取機會的差異使一些人無法得到及時的診斷和治療。這些限制加劇了診斷不足和治療延誤，並阻礙了重要資訊和治療方法的普及，從而限制了受影響人群中陰道炎的有效治療。

遠端醫療的普及將加速

由於遠距醫療與遠距離診斷和治療的結合，遠端醫療的日益普及為陰道炎治療藥物市場帶來了機會。隨著遠端醫療的擴展，需要準確的輻射監測工具。這些設備透過遠端評估遠端醫療期間的輻射暴露（包括診斷影像和放射治療），對於確保患者安全至關重要。支援遠端醫療的輻射檢測技術創新為開發攜帶式、易於使用且準確的檢測器以開拓這一新興市場提供了機會。

臨床試驗挑戰

有限的教育和資源阻礙了適當輻射安全措施的實施和對檢測技術的理解。因此，患者和醫護人員遭受輻射過度的風險增加，可能會產生健康後果。此外，缺乏嚴格的法規和基礎設施投資不足進一步加劇了這一問題，可能導致與輻射相關的健康併發症率更高，以及對先進檢測解決方案的需求不足，從而阻礙了市場成長。

COVID-19 的影響：

COVID-19 的爆發正在透過改變醫療保健優先事項來影響市場。由於醫療保健系統專注於大流行病的防範，注意力和資源已經從陰道炎等非緊急情況轉移。醫療保健取得、供應鏈和患者行為的中斷也影響了診斷和尋求治療的模式，從而影響了大流行期間陰道炎治療的市場動態。

處方藥市場預計將在預測期內成為最大的市場

由於慢性病盛行率不斷上升以及對專門醫療干預措施的需求不斷增加，因此處方藥細分市場預計在預測期內將成長最快。隨著醫療保健意識的提高，對解決特定健康問題的處方藥的需求激增。此外，監管部門的核准和藥物研究的進步也促進了這一領域的崛起。

預計線上藥房領域在預測期內將出現最高的複合年成長率

由於醫療保健服務的數位化、便利性和可及性不斷提高，預計線上藥局產業在預測期內將實現高成長率。線上藥局提供了一個有吸引力的解決方案，因為消費者優先考慮在舒適的家中購買藥品的便利性。遠端醫療的採用和電子商務的進步正在推動該領域的快速成長。

比最大的地區

北美能夠主導市場，主要是因為其先進的醫療基礎設施、較高的意識以及對女性健康的關注。該地區領先的市場佔有率得到了成熟的研發活動、強大的法規結構以及積極採用創新治療方法的進一步支持。陰道炎盛行率的不斷上升，加上人口老化的加劇，增加了對有效治療方法的需求，使北美成為在陰道炎治療藥物市場上佔據最大市場佔有率的關鍵參與者。我們正在加強我們的作用。

複合年成長率最高的地區：

由於意識的提高、醫療保健基礎設施的增加以及對女性健康的日益關注，亞太地區正在經歷強勁的市場成長。醫療保健服務的改善、生活方式的改變以及陰道炎盛行率上升等因素促進了該地區的擴張態勢。此外，醫學研究和技術的進步，加上政府的支持舉措，為市場開拓和創新陰道炎治療方法的採用創造了有利的環境，推動了亞太地區市場的顯著成長。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球陰道炎治療藥物市場：依疾病類型

  • 萎縮性陰道炎
  • 細菌性陰道炎（BV）
  • 滴蟲病
  • 外陰陰道念珠菌症(​​VVC)
  • 其他疾病類型

第6章全球陰道炎治療藥物市場：依治療分類

  • 處方藥
  • 天然和草藥療法
  • 成藥(OTC)
  • 益生菌和陰道塞劑

第7章全球陰道炎治療藥物市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他分銷管道

第8章全球陰道炎治療藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Astellas Pharma
  • AstraZeneca PLC
  • Bausch Health Companies Inc
  • Bayer AG
  • Biocon Limited
  • Cipla Inc.
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
Product Code: SMRC24909

According to Stratistics MRC, the Global Vaginitis Therapeutics Market is accounted for $3.52 billion in 2023 and is expected to reach $7.01 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Vaginitis therapeutics encompasses medical interventions aimed at treating inflammation or infection of the vagina, a condition known as vaginitis. Common causes include bacterial, fungal or viral infections and treatment often involves antimicrobial medications, antifungals, or antivirals. Additionally, managing underlying factors like hormonal imbalances or irritants is crucial. Personalized care may include topical or oral medications, lifestyle modifications and addressing contributing factors to alleviate symptoms and restore vaginal health.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals.

Market Dynamics:

Driver:

Heightened awareness about women's health and vaginal infections

Increased awareness about women's health and vaginal infections acts as a pivotal driver in vaginitis therapeutics. It fosters a proactive approach to healthcare, encouraging women to recognize symptoms early, seek prompt medical attention and adopt preventive measures. This awareness promotes education initiatives, facilitates open discussions and reduces stigma surrounding vaginal health issues. Consequently, it leads to improved healthcare-seeking behaviour, earlier diagnosis, and timely intervention, driving the demand for effective therapies.

Restraint:

Limited healthcare access

Limited healthcare access serves as a significant restraint in vaginitis therapeutics. It encompasses various barriers such as inadequate healthcare infrastructure, especially in rural or underserved areas, leading to reduced availability of medical facilities and specialists. Additionally, financial constraints and disparities in access prevent some individuals from seeking timely diagnosis and treatment. This limitation exacerbates underdiagnosis, delays in care and impedes the dissemination of crucial information and treatments, thereby restricting effective management of vaginitis among affected populations.

Opportunity:

Increasing adoption of telemedicine facilitates

The growing adoption of telehealth presents an opportunity in the vaginitis therapeutics market due to its integration with remote diagnostics and treatments. As telehealth expands, there is a need for accurate radiation monitoring tools. These devices become crucial in ensuring patient safety by remotely assessing radiation exposure during telemedicine sessions involving imaging or radiation therapies. Innovations in radiation detection technologies catering to telehealth settings offer a chance for companies to develop portable, user-friendly, and precise detectors, thereby tapping into this evolving market demand.

Threat:

Clinical trial challenges

Limited education and resources hinder the adoption of proper radiation safety measures and the understanding of detection technologies. This can lead to increased risks of overexposure to radiation for both patients and healthcare workers, impacting their health. Additionally, the absence of stringent regulations and insufficient infrastructure investment further exacerbate this issue, potentially resulting in higher incidences of radiation-related health complications and impeding the market's growth due to a lack of demand for advanced detection solutions.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by altering healthcare priorities. With healthcare systems focusing on combating the pandemic, attention and resources shifted away from non-emergency conditions like vaginitis. Disruptions in healthcare access, supply chains, and patient behaviour also affected diagnosis and treatment-seeking patterns, impacting the market dynamics for vaginitis therapeutics during the pandemic period.

The prescription drugs segment is expected to be the largest during the forecast period

The prescription drugs segment is anticipated to be the largest during the forecast period owing to the growing prevalence of chronic diseases and the increasing need for specialized medical interventions. As healthcare awareness rises, there is a surge in demand for prescription medications to address specific health conditions. Additionally, regulatory approvals and advancements in pharmaceutical research contribute to the prominence of this segment.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to achieve a high growth rate during the forecast period due to increasing digitalization, convenience and accessibility of healthcare services. As consumers prioritise the ease of purchasing medications from the comfort of their homes, online pharmacies offer a compelling solution. The adoption of telemedicine, coupled with advancements in e-commerce, fosters the rapid growth of this segment.

Region with largest share:

North America is positioned to dominate the market, primarily attributed to advanced healthcare infrastructure, high awareness levels, and a robust emphasis on women's health. The region's leading market share is further propelled by well-established research and development activities, a strong regulatory framework, and a proactive approach toward adopting innovative therapies. Increasing incidences of vaginitis, coupled with a growing aging population, contribute to the demand for effective therapeutics, reinforcing North America's pivotal role in capturing the largest market share in the vaginitis therapeutics market.

Region with highest CAGR:

The Asia-Pacific region is experiencing significant growth in the market due to rising awareness, increasing healthcare infrastructure and a growing emphasis on women's health. Factors such as improved access to healthcare services, changing lifestyles, and a rising incidence of vaginitis contribute to the region's poised expansion. Additionally, advancements in medical research and technology, coupled with supportive government initiatives, create a favourable environment for the development and adoption of innovative vaginitis therapeutics, driving substantial market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Vaginitis Therapeutics Market include Astellas Pharma, AstraZeneca PLC, Bausch Health Companies Inc, Bayer AG, Biocon Limited, Cipla Inc., Ferring Pharmaceuticals, GlaxoSmithKline plc, Hologic, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Perrigo Company plc, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc.

Key Developments:

In January 2023, Astellas Pharma acquired Shionogi & Co.'s global women's health franchise, which includes the Vagifem vaginal ring for the treatment of recurrent vulvovaginal candidiasis (RVVC).

In May 2022, Bayer acquired FemTec, including Vagisan, a vaginal moisturizer. Additionally, Seres Therapeutics introduced SER-109, a microbiome-based therapy for recurrent vulvovaginal candidiasis (RVVC).

In April 2022, Pfizer introduced Daivobet, a topical cream combining steroids and vitamin D, designed to treat vulvovaginal candidiasis (VVC). Daivobet stands as the sole FDA-approved topical cream with this combination for VVC treatment.

Disease Types Covered:

  • Atrophic Vaginitis
  • Bacterial vaginosis (BV)
  • Trichomoniasis
  • Vulvovaginal Candidiasis (VVC)
  • Other Disease Types

Treatments Covered:

  • Prescription Drugs
  • Natural and Herbal Remedies
  • Over-the-counter (OTC) Drugs
  • Probiotics and Vaginal Suppositories

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaginitis Therapeutics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Atrophic Vaginitis
  • 5.3 Bacterial vaginosis (BV)
  • 5.4 Trichomoniasis
  • 5.5 Vulvovaginal Candidiasis (VVC)
  • 5.6 Other Disease Types

6 Global Vaginitis Therapeutics Market, By Treatment

  • 6.1 Introduction
  • 6.2 Prescription Drugs
  • 6.3 Natural and Herbal Remedies
  • 6.4 Over-the-counter (OTC) Drugs
  • 6.5 Probiotics and Vaginal Suppositories

7 Global Vaginitis Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Vaginitis Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Astellas Pharma
  • 10.2 AstraZeneca PLC
  • 10.3 Bausch Health Companies Inc
  • 10.4 Bayer AG
  • 10.5 Biocon Limited
  • 10.6 Cipla Inc.
  • 10.7 Ferring Pharmaceuticals
  • 10.8 GlaxoSmithKline plc
  • 10.9 Hologic, Inc.
  • 10.10 Johnson & Johnson
  • 10.11 Lupin Pharmaceuticals, Inc.
  • 10.12 Merck & Co., Inc.
  • 10.13 Mylan N.V.
  • 10.14 Novartis AG
  • 10.15 Perrigo Company plc
  • 10.16 Pfizer Inc.
  • 10.17 Sanofi
  • 10.18 Sun Pharmaceutical Industries Ltd.
  • 10.19 Teva Pharmaceutical Industries Ltd.
  • 10.20 TherapeuticsMD, Inc.

List of Tables

  • Table 1 Global Vaginitis Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 4 Global Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 5 Global Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 6 Global Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 7 Global Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 8 Global Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 10 Global Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 11 Global Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 12 Global Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 13 Global Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 14 Global Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 15 Global Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 17 Global Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 18 North America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 20 North America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 21 North America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 22 North America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 23 North America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 24 North America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 25 North America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 26 North America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 27 North America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 28 North America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 29 North America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 30 North America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 North America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 North America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 North America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 North America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Europe Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 37 Europe Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 38 Europe Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 39 Europe Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 40 Europe Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 41 Europe Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 42 Europe Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 43 Europe Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 44 Europe Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 45 Europe Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 46 Europe Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 47 Europe Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 48 Europe Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 49 Europe Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 50 Europe Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 51 Europe Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 52 Asia Pacific Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 54 Asia Pacific Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 55 Asia Pacific Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 56 Asia Pacific Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 57 Asia Pacific Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 58 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 59 Asia Pacific Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 60 Asia Pacific Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 61 Asia Pacific Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 62 Asia Pacific Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 63 Asia Pacific Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 64 Asia Pacific Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 65 Asia Pacific Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 66 Asia Pacific Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 67 Asia Pacific Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 68 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 69 South America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 71 South America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 72 South America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 73 South America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 74 South America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 75 South America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 76 South America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 77 South America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 78 South America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 79 South America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 80 South America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 81 South America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 82 South America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 83 South America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 84 South America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 85 South America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 86 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 88 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 89 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 90 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 91 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 92 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 93 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 94 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 95 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 97 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 98 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 99 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 100 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 101 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 102 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)